Anterior Spinal Artery Syndrome

1. Disease Information

Overview

Anterior Spinal Artery Syndrome (ASAS) is an ischemic myelopathy resulting from occlusion or hypoperfusion of the anterior spinal artery or its feeding radiculomedullary arteries. The anterior spinal artery supplies the ventral two-thirds of the spinal cord, including the corticospinal tracts, spinothalamic tracts, and anterior horn motor neurons, while sparing the dorsal columns. This vascular territory explains the hallmark dissociated sensory loss: pain and temperature sensation are lost while proprioception and vibration are preserved. ASAS is a medical emergency with significant morbidity and mortality. The syndrome is most commonly associated with aortic pathology but can also result from embolic events, vasculitis, and other vascular causes.

Key Identifiers

Synonyms and Alternative Names

• Anterior spinal artery syndrome
• Anterior spinal cord syndrome
• Anterior cord syndrome
• Beck syndrome
• Anterior spinal artery occlusion syndrome
• Ventral spinal cord syndrome
• Spinal cord anterior artery syndrome

Data Sources

This characterization is derived from aggregated disease-level resources including published clinical series, case reports, review articles, and biomedical ontology databases. No individual patient-level EHR data were used. A total of 107 papers were reviewed for this report.

2. Etiology

Disease Causal Factors

ASAS is fundamentally a vascular/ischemic disorder caused by interruption of blood flow through the anterior spinal artery or its feeder vessels. The primary causal mechanism is arterial occlusion (thrombotic, embolic, or hemodynamic) leading to ischemic infarction of the anterior two-thirds of the spinal cord.

Etiological breakdown from major clinical series:

In a landmark 19.8-year cohort study of 55 consecutive spinal cord ischemia patients: "Aetiologies of infarcts were arteriosclerosis of the aorta and vertebral arteries (23.6%), aortic surgery or interventional aneurysm repair (11%) and aortic and vertebral artery dissection (11%), and in 23.6%, aetiology remained unclear" (PMID: 25398656).

In a separate series of 36 spinal cord infarction patients: "the commonest group being spinal cord ischemia due to idiopathic causes (36.1%). Following these, there were cases associated with aortic surgery (25%), systemic arteriosclerosis (19.4%) and acute deficit of perfusion (11.1%)" (PMID: 11641795).

Specific etiological categories include:

1. Aortic pathology (most common identifiable cause): Aortic dissection (Type A and B), aortic aneurysm with mural thrombus (PMID: 29506472), thoracic endovascular aortic repair (TEVAR), open thoracoabdominal aortic surgery (PMID: 12483181), intra-aortic balloon pump complications (PMID: 27736197)

2. Fibrocartilaginous embolism (rare, younger patients): "Fibrocartilaginous nucleus pulposus components herniation and embolism rarely causes acute ischaemic events involving the spinal cord. Few reports have suggested this as a mechanism leading to anterior spinal artery syndrome" (PMID: 36114979)

3. Vasculitis: Behçet's disease (PMID: 22892002, PMID: 22193225), systemic lupus erythematosus (PMID: 29900713)

4. Iatrogenic: Spinal surgery complications (PMID: 32502625), spinal anesthesia (PMID: 27184089)

5. Hypercoagulable states: COVID-19-associated coagulopathy (PMID: 38365009)

6. Vertebral artery occlusion/dissection: (PMID: 41137336)

7. Hemodynamic: Systemic hypotension, cardiac arrest (PMID: 41690059)

Risk Factors

Cardiovascular risk factors: Smoking, hypertension, diabetes mellitus, and hypercholesterolemia are identified as the major risk factors (PMID: 22962400). Mean age at presentation is approximately 59.3 years (PMID: 11641795), with male predominance (66.6% in some series — PMID: 38365009).

Surgical/procedural risk factors: Prolonged aortic cross-clamp time (PMID: 12483181), coverage of the left subclavian artery during TEVAR (PMID: 29788799), hyperkyphosis correction, combined anterior-posterior spinal procedures (PMID: 32871559).

A predictive risk score (0–6 points) for SCI after open TAAA repair achieved AUC 0.919, based on: TAAA extent II, BMI ≥30, smoking history, preoperative diuretic use, age >70, and chronic kidney disease (PMID: 41205836).

Anatomic risk factors: Variant spinal cord arterial supply with limited collateral networks, anomalously low origin of the artery of Adamkiewicz (PMID: 12483181).

Genetic risk factors: No specific genetic variants are causal for ASAS. However, genetic conditions affecting vascular integrity (Marfan syndrome — FBN1; Loeys-Dietz syndrome — TGFBR1/TGFBR2; vascular Ehlers-Danlos — COL3A1) predispose to aortic pathology which can secondarily cause ASAS.

Protective Factors

• Robust collateral arterial networks (complete Circle of Willis, well-developed segmental medullary arteries)
• Multiple radiculomedullary arteries (present in ~32% of individuals — PMID: 36152330)
• Dominant anterior thoracic artery present in 94% of individuals (PMID: 36581455)
• Cardiovascular risk factor modification (BP control, lipid management, smoking cessation)
• Perioperative spinal cord protection protocols (CSF drainage, staged repair, MISACE — PMID: 41418893)

Gene-Environment Interactions

No specific gene-environment interactions have been characterized for ASAS. The disease is predominantly acquired through vascular mechanisms rather than genetic predisposition.

3. Phenotypes

Core Clinical Presentation

ASAS presents with a characteristic triad. As described in a comprehensive review: "Acute occlusion of the anterior spinal artery and subsequent spinal ischemic infarction leads to anterior spinal artery syndrome characterized by back pain and bilateral flaccid paresis with loss of protopathic sensibility" (PMID: 37164315).

In a clinical series of 17 patients: "Clinical presentation included dissociative anesthesia, weakness of limbs, back or neck pain, and autonomic symptoms with symptom onset to peak time ranging from few minutes to 48 hours" (PMID: 30093205).

The syndrome accounts for 49% of spinal cord ischemia: "49% of patients suffered from centromedullar syndrome caused by anterior spinal artery ischemia" (PMID: 25398656).

Phenotype Catalog

Pediatric Phenotype

In children/adolescents, fibrocartilaginous embolism is the most characteristic cause. Mean age at presentation is 13.2 years. All 7 children in one series had bladder dysfunction requiring catheterization, and neurogenic bladder persisted in 6/7 at last follow-up (PMID: 28578817).

Quality of Life Impact

ASAS has a devastating impact on quality of life. At discharge, 57.1% of patients are wheelchair users, 25% are ambulatory with technical aids, and only 17.9% achieve full ambulation (PMID: 11641795). Neurogenic bladder dysfunction persists in the majority of patients long-term.

4. Genetic/Molecular Information

Causal Genes

ASAS is not a Mendelian genetic disorder. No causal genes, pathogenic variants, or chromosomal abnormalities are directly responsible. It is an acquired vascular condition.

Relevant Genetic Context

Genes involved in predisposing conditions include:

Molecular Pathways in Ischemia-Reperfusion Injury

The molecular cascades activated during spinal cord ischemia are well-characterized from preclinical research:

• PI3K/Akt/GSK-3β pathway: Neuroprotective signaling; astaxanthin activation improves outcomes (PMID: 32703256)
• Nrf2/HO-1 pathway: Antioxidant defense; targeted by hydrogen therapy and melatonin (PMID: 41579273, PMID: 40684392)
• NF-κB signaling: Pro-inflammatory cascade activation
• NLRP3 inflammasome: Drives pyroptosis and neuroinflammation
• HMGB1 signaling: Anti-HMGB1 antibody therapy improved neurological outcomes in a rabbit SCIRI model: "Treatment with anti-HMGB1 mAb significantly improved neurological outcomes, reduced the extent of spinal cord infarction, preserved motor neuron viability, and decreased the presence of activated microglia and infiltrating neutrophils" (PMID: 40943562)
• CaMKII pathway: Inhibition with tatCN19o showed neuroprotective effects in mouse spinal cord ischemia model (PMID: 40885467)

Epigenetic and Chromosomal Information

No disease-specific epigenetic changes or chromosomal abnormalities have been described for ASAS.

5. Environmental Information

Environmental Factors

• Iatrogenic: Aortic surgery (open repair, TEVAR), spinal surgery, spinal anesthesia, intra-aortic balloon pump use — the most significant modifiable risk factors
• Trauma: Cervical facet dislocation (VA occlusion in 24% — PMID: 39043672), minor physical trauma triggering fibrocartilaginous embolism
• Atherosclerotic burden: Smoking, hypertension, hyperlipidemia, diabetes

Lifestyle Factors

• Smoking: Major vascular risk factor (PMID: 22962400)
• Intense physical activity: Paradoxically, a trigger for fibrocartilaginous embolism in young patients; the most common trigger event in pediatric cases was intense exercise or sports (PMID: 31201068)
• Sedentary lifestyle/metabolic syndrome: Contributes to vascular risk

Infectious Agents

SARS-CoV-2: COVID-19-associated coagulopathy linked to spinal cord ischemia. In a systematic review: "Sixty-six percent of the patients had severe COVID-19. Five data sets reported preexisting coagulopathy. ... Anterior spinal artery lesions were the most prevalent ischemic pattern" (PMID: 38365009).

6. Mechanism / Pathophysiology

The Causal Chain

INITIAL TRIGGER
    │
    ├── Aortic pathology (atherosclerosis, dissection, surgery)
    ├── Embolism (cardiac, fibrocartilaginous, atheromatous)
    ├── Hypoperfusion (hypotension, cardiac arrest)
    └── Vessel compression/occlusion
    │
    ▼
VASCULAR OCCLUSION/HYPOPERFUSION
    │
    ├── Anterior spinal artery occlusion
    ├── Radiculomedullary artery occlusion (e.g., artery of Adamkiewicz)
    └── Sulcal/sulcocommissural artery occlusion
    │
    ▼
SPINAL CORD ISCHEMIA (ventral 2/3)
    │
    ├── Energy failure (ATP depletion)
    ├── Excitotoxicity (glutamate release)
    ├── Calcium influx → CaMKII activation
    │
    ▼
SECONDARY INJURY CASCADES
    │
    ├── Oxidative stress (ROS generation) ──→ Nrf2/HO-1 pathway
    ├── Neuroinflammation ──→ NF-κB, NLRP3 inflammasome, HMGB1
    ├── Apoptosis ──→ Caspase cascades
    ├── Ferroptosis ──→ GPX4 pathway
    ├── Pyroptosis ──→ Gasdermin-D
    └── Autophagy dysregulation
    │
    ▼
NEURONAL AND GLIAL CELL DEATH
    │
    ├── Anterior horn motor neuron destruction → Flaccid paralysis
    ├── Spinothalamic tract damage → Loss of pain/temperature
    ├── Corticospinal tract damage → Upper motor neuron signs (late)
    └── Autonomic pathway damage → Bladder/bowel dysfunction
    │
    ▼
CLINICAL MANIFESTATION: ASAS TRIAD

Vascular Anatomy

The spinal cord receives blood supply from three longitudinal arteries. The single midline ASA (UBERON:0005431) is formed by branches from the vertebral arteries and reinforced by radiculomedullary arteries at various segmental levels. The artery of Adamkiewicz, the largest feeder, originates at T9-T12 on the left side in ~81% of individuals (PMID: 36152330). The mid-thoracic region (T4-T8) is a watershed zone particularly vulnerable to ischemia.

The left and right anterior radiculomedullary arteries show distinct distributions: 252 arteries from C2-C8 were slightly dominant on the right, while 236 arteries from T1-L2 were obviously dominant on the left, with the transition occurring at C8-T1 (PMID: 31399898).

Molecular Mechanisms

As described in a comprehensive review: "Oxidative stress is an important pathological event of ischemia/reperfusion injury. Oxidative stress can initiate multiple inflammatory and apoptotic pathways, triggering a series of destructive events such as inflammatory responses and cell death, further deteriorating the microenvironment at the injured site, and leading to neurological dysfunction" (PMID: 40630671).

Key signaling pathways:

Cellular Processes (GO Terms)

• Apoptotic process (GO:0006915)
• Inflammatory response (GO:0006954)
• Response to oxidative stress (GO:0006979)
• Response to ischemia (GO:0002931)
• Autophagy (GO:0006914)
• Cell death (GO:0008219)

Cell Types Involved (CL Terms)

Immune System Involvement

Neuroinflammation is critical to secondary injury. Anti-HMGB1 therapy "significantly improved neurological outcomes, reduced the extent of spinal cord infarction, preserved motor neuron viability, and decreased the presence of activated microglia and infiltrating neutrophils" (PMID: 40943562). Autoimmune vasculitis (Behçet's disease, SLE) represents a distinct subset.

7. Anatomical Structures Affected

Organ Level

Primary: Spinal cord (UBERON:0002240), anterior spinal artery (UBERON:0005441)

Secondary: Urinary bladder, gastrointestinal tract, skeletal muscle (atrophy), skin (pressure injuries), lungs (high cervical lesions)

Body systems: Nervous (primary), cardiovascular (underlying cause), urinary, musculoskeletal

Tissue and Cell Level

Subcellular Level

• Mitochondria (GO:0005739): Energy failure, ROS generation
• Endoplasmic reticulum (GO:0005783): ER stress
• Cell membrane: Lipid peroxidation, ion channel dysfunction
• Nucleus (GO:0005634): DNA damage, apoptotic signaling

Localization

• Thoracic spinal cord (UBERON:0003038): Most commonly affected (watershed zone)
• Cervical spinal cord (UBERON:0002726): When cervical ASA occluded — bilateral arm paresis (PMID: 10773652)
• Conus medullaris: "Snake-eye appearance" on MRI (PMID: 36998945)
• Lateralization: Typically bilateral and symmetric, but unilateral presentations occur with sulcal artery occlusion (PMID: 40104967, PMID: 30300819)

8. Temporal Development

Onset

• Typical age: Adult-onset, mean ~59 years (PMID: 11641795); pediatric cases mean 13.2 years (PMID: 28578817)
• Onset pattern: Acute to hyperacute — minutes to 48 hours to peak (PMID: 30093205)
• Typically preceded by sudden back pain

Progression

• Disease course: Monophasic (single event); chronic residual deficits; NOT relapsing-remitting
• Recovery timeline: In 9 patients followed 15–41 months: 4 walked independently, 1 with support (PMID: 30093205)

Critical Periods

• First 4.5–6 hours: Window for potential thrombolytic therapy (PMID: 22962400, PMID: 26386968)
• First 24 hours: Critical for hemodynamic augmentation and CSF drainage
• First 3–4 months: Period of most significant functional recovery (PMID: 22193225)
• Delayed SCI after TEVAR: Can occur months to years post-procedure (PMID: 38304669)

9. Inheritance and Population

Epidemiology

ASAS is rare. Spinal cord infarction accounts for ~1–2% of all strokes. ASAS represents ~49% of spinal cord ischemia cases (PMID: 25398656). Estimated incidence of all spinal cord infarction is approximately 3.1 per 100,000 person-years. After aortic surgery, SCI incidence ranges from 0–10.6% for TEVAR to 0–35% for thoracoabdominal repair (PMID: 34740806).

Inheritance

Not applicable — ASAS is an acquired vascular condition with no Mendelian inheritance pattern. Predisposing conditions (Marfan, vascular EDS) follow autosomal dominant inheritance.

Population Demographics

• Sex ratio: Male predominance (~60–67%) (PMID: 38365009)
• Age distribution: Bimodal — peak in adolescents (fibrocartilaginous embolism) and older adults (atherosclerotic/surgical causes)
• Geographic distribution: Worldwide; correlates with cardiovascular disease burden
• Ethnic predisposition: None documented; risk mirrors cardiovascular disease prevalence

10. Diagnostics

MRI (Gold Standard)

MRI findings are highly characteristic. In anterior spinal artery infarcts: "MRI findings in anterior spinal artery infarcts included pencillike hyperintensities on T2 sagittal (n = 16, 100%) and 'owl eye' appearance on T2 axial (n = 6, 37.5%) images. Diffusion restriction was noted in 8 cases and enhancement was noted in 2 cases" (PMID: 30093205).

The "snake-eye appearance" on axial MRI in conus infarction: "acute onset of conus medullaris syndrome combined with 'snake-eye appearance' should be strongly suspected as conus medullaris infarction caused by anterior spinal artery ischemia" (PMID: 36998945).

Additional Diagnostic Studies

• CT angiography of aorta: Identify dissection, aneurysm, atherosclerosis
• Digital subtraction angiography: May show ASA occlusion (PMID: 16718293)
• CSF analysis: Elevated protein without pleocytosis (distinguishes from inflammatory myelitis); exclude AQP4/MOG antibodies (PMID: 41137336)
• Electrophysiology: Absent CMAPs predict poor prognosis — "CMAP could be seen a marker of prognosis for ASAS patients, and absent CMAP might forecast the bad prognosis" (PMID: 16718293)
• ASIA Impairment Scale: Standard neurological classification (A through E)

Genetic Testing

Not applicable for ASAS itself. Relevant for underlying predisposing conditions (thrombophilia panel, connective tissue disorder genes) in young patients without clear etiology.

Differential Diagnosis

11. Outcome / Prognosis

Survival and Mortality

In the largest published series (36 patients): "the average age of the patients was 59.3 years, with a mortality of 22.2% during the hospital stay. Regarding the functional outcomes at the moment of discharge, it must be pointed out that 57.1% of the patients were wheelchair users, 25% were ambulatory, using technical aids, and 17.9% were fully ambulatory" (PMID: 11641795).

Prognostic Factors

"Prognosis is primarily determined by the severity of motor or sensory involvement, in particular, initial and nadir ASIA A/B scores which strongly correlate with poor outcome. In the majority of series, 40-60% of patients had initial ASIA A/B scores with a similar proportion remaining wheelchair dependent on follow-up" (PMID: 26154150).

Complications

Deep vein thrombosis, pulmonary embolism, urinary tract infections, pressure ulcers, chronic neuropathic pain, spasticity, pneumonia (cervical lesions), depression, neurogenic bladder (persistent in 6/7 pediatric patients — PMID: 28578817).

12. Treatment

Current Management

There is no disease-specific pharmacotherapy for ASAS. Treatment is largely supportive and empirical.

Acute phase:

Rehabilitation (cornerstone of long-term management): - Physical therapy (MAXO:0000011), occupational therapy (MAXO:0000535) - Bladder management (intermittent catheterization — MAXO:0000474) - Pain management (gabapentin, pregabalin for neuropathic pain) - Psychological support - Satisfactory functional recovery may require 3–4 months; complete independence achievable at 1 year in favorable cases (PMID: 22193225)

Experimental/Preclinical Therapeutics

Perioperative Prevention Strategies

• Intraoperative neuromonitoring (MEPs, SSEPs)
• Staged procedures for extensive aortic coverage
• MISACE before fenestrated/branched endovascular repair: SCI 9.5% vs 30% without (PMID: 41418893)
• Minimizing aortic cross-clamp time
• Multimodal spinal cord protection bundles (PMID: 34740806)

13. Prevention

Primary Prevention

• Cardiovascular risk factor modification (smoking cessation, BP control, lipid management, diabetes control)
• Atherosclerosis prevention
• Anticoagulation for thrombophilic states/atrial fibrillation

Secondary Prevention (Perioperative)

• Cerebrospinal fluid drainage protocols (PMID: 34740806)
• Blood pressure augmentation (MAP >80–90 mmHg)
• Intraoperative neuromonitoring (PMID: 32502625)
• Staged aortic repair
• MISACE (PMID: 41418893)
• Avoidance of prolonged hypotension (PMID: 12483181)

Tertiary Prevention

• DVT prophylaxis, pressure ulcer prevention, UTI prevention
• Respiratory care (high cervical lesions)
• Spasticity management
• Psychological support

14. Other Species / Natural Disease

Naturally Occurring Disease

Dogs (NCBI Taxon: 9615): Fibrocartilaginous embolism causing spinal cord infarction is well-recognized in veterinary medicine. "The disease has been found more frequently in dogs" (PMID: 7202135). Large and giant breed dogs are most commonly affected. The canine model has provided important insights into the pathogenesis of nucleus pulposus embolism.

Horses (NCBI Taxon: 9796): Spinal cord ischemia reported from fibrocartilaginous embolism or verminous arteritis.

Cats (NCBI Taxon: 9685): Rare reports of fibrocartilaginous embolism.

Pigs (NCBI Taxon: 9823): Used as experimental models due to similar vascular anatomy (PMID: 32115761).

Comparative Biology

Spinal cord vascular anatomy is conserved across mammals. The vulnerability of the ASA territory to ischemia is a shared feature due to the precarious watershed blood supply. Fibrocartilaginous embolism occurs across multiple mammalian species, suggesting a conserved pathomechanism.

15. Model Organisms

Animal Models of Spinal Cord Ischemia

Model Characteristics

Phenotype recapitulation: Rodent models reliably produce hind limb motor deficits. Histological changes include motor neuron loss, vacuolization, and pyknosis in lumbar anterior horn (PMID: 40885467). Molecular cascades mirror human pathophysiology.

Limitations: Small animal models lack the complex arterial anatomy of humans. Aortic cross-clamp models cause global ischemia rather than isolated ASA territory infarction. Recovery mechanisms may differ between species. Porcine models most closely approximate human spinal vascular anatomy.

Key Findings Summary

F1: Disease Definition and Identifiers

ASAS (MONDO:0006650) is ischemia/infarction in the distribution of the anterior spinal artery, affecting the ventral two-thirds of the spinal cord. Key identifiers include MeSH D020759, SNOMED CT 2972007, DOID 6712, and UMLS C0221069.

F2: Multiple Vascular Etiologies with Aortic Disease Predominant

Aortic pathology (atherosclerosis, dissection, surgery) accounts for 35–50% of identifiable cases. Fibrocartilaginous embolism is rare but important in young patients. 20–36% remain idiopathic.

F3: Characteristic Clinical Triad

Motor paralysis, dissociated sensory loss (pain/temperature lost, proprioception preserved), and autonomic dysfunction. Symptom onset to peak ranges from minutes to 48 hours.

F4: Poor Prognosis with Variable Recovery

In-hospital mortality ~22%. At discharge: 57% wheelchair-dependent, 25% ambulatory with aids, 18% fully ambulatory. Initial ASIA A/B scores strongly predict poor outcome.

F5: Pathognomonic MRI Features

Pencil-like T2 hyperintensity (100%), "owl eye" sign (37.5%), diffusion restriction, and cord swelling. "Snake-eye appearance" in conus infarction.

F6: Ischemia-Reperfusion Molecular Cascades

Oxidative stress, neuroinflammation (NF-κB, NLRP3, HMGB1), apoptosis, ferroptosis, and pyroptosis represent key pathophysiological mechanisms with multiple potential therapeutic targets.

Limitations and Knowledge Gaps

1. Limited epidemiological data: No population-based incidence/prevalence studies exist specifically for ASAS
2. No randomized controlled trials: All treatments based on case reports/series; Level I evidence completely lacking
3. Diagnostic delay: Initial MRI may be normal in some cases; DWI not always acquired
4. No validated biomarkers: Beyond electrophysiological markers (CMAPs), no serum/CSF biomarkers for early diagnosis
5. Translational gap: Numerous preclinical neuroprotective agents but none translated to clinical use
6. Idiopathic cases: 20–36% have no identifiable etiology
7. Sparse long-term data: Follow-up beyond 2–3 years poorly characterized
8. No human omics data: All molecular pathway data from animal models
9. Pediatric knowledge gap: Pathogenesis of childhood idiopathic SCI remains unclear (PMID: 28578817)

Proposed Follow-up Experiments / Actions

1. Multicenter prospective ASAS registry — Standardized data collection on incidence, etiology, treatment, and outcomes
2. Biomarker discovery — Proteomics/metabolomics of CSF and serum in acute ASAS (neurofilament light, GFAP, S100B)
3. Thrombolysis clinical trial — Multicenter trial of IV rt-PA for acute ASAS (after excluding dissection/hemorrhage)
4. CaMKII inhibitor translational studies — Advance tatCN19o from mouse to large animal models
5. Anti-HMGB1 therapy development — Advance from rabbit models toward clinical translation
6. Standardized emergency MRI protocol — Include mandatory DWI sequences and optimized timing
7. Genetic susceptibility studies — GWAS in idiopathic ASAS patients
8. Single-cell transcriptomics — Map cell-type-specific responses at multiple post-ischemia time points
9. Rehabilitation RCTs — Compare early intensive rehabilitation to standard care
10. Preoperative spinal vascular mapping — Non-invasive MR angiography for high-risk aortic surgery patients

Evidence Base — Key Citations

Report generated: 2026-05-05 Based on systematic analysis of 107 published studies and 6 confirmed findings Disease: Anterior Spinal Artery Syndrome (MONDO:0006650)